DK2280732T3 - Antistoffer mod granulocyt-makrofag-koloni-stimulerende faktor - Google Patents

Antistoffer mod granulocyt-makrofag-koloni-stimulerende faktor Download PDF

Info

Publication number
DK2280732T3
DK2280732T3 DK09739607.1T DK09739607T DK2280732T3 DK 2280732 T3 DK2280732 T3 DK 2280732T3 DK 09739607 T DK09739607 T DK 09739607T DK 2280732 T3 DK2280732 T3 DK 2280732T3
Authority
DK
Denmark
Prior art keywords
antibody
csf
region
human
sequences
Prior art date
Application number
DK09739607.1T
Other languages
English (en)
Inventor
Christopher R Bebbington
Kenneth Luehrsen
Geoffrey T Yarranton
Original Assignee
Humanigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humanigen Inc filed Critical Humanigen Inc
Application granted granted Critical
Publication of DK2280732T3 publication Critical patent/DK2280732T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)

Claims (7)

1. Anti-GM-CSF-antistof, omfattende: (a) en VH-region der omfatter aminosyresekvensen af SEQ ID NO: 5; og (b) en Vi_-region der omfatter aminosyresekvensen af SEQ ID NO:7.
2. Anti-GM-CSF-antistoffet ifølge krav 1, hvor antistoffet er et IgG.
3. Anti-GM-CSF-antistoffet ifølge krav 1 eller 2, hvor antistoffet omfatter en tungkæde konstant-region med aminosyresekvensen som fremsat i SEQ ID NO: 11 og en kappa-letkæde konstant-region med aminosyresekvensen som fremsat i SEQ ID NO: 10.
4. Farmaceutisk sammensætning omfattende et anti-GM-CSF-antistof ifølge et hvilket som helst af kravene 1 til 3.
5. Anti-GM-CSF-antistof ifølge et hvilket som helst af kravene 1 til 3 til anvendelse som et medikament.
6. Anti-GM-CSF-antistof ifølge et hvilket som helst af kravene 1 til 3 til anvendelse i behandling af en patient der har en kronisk inflammatorisk sygdom.
7. Anti-GM-CSF-antistof ifølge et hvilket som helst af kravene 1 til 3 til anvendelse i behandling af en patient der har osteopeni, rheumatoid arthritis, astma, multipel sklerose, psoriasis, kronisk obstruktiv lungesygdom, idiopatisk thrombocytopeni purpura, hjertesvigt, hjerteskade på grund af en iskæmisk hændelse, eller diabetes.
DK09739607.1T 2008-04-28 2009-04-28 Antistoffer mod granulocyt-makrofag-koloni-stimulerende faktor DK2280732T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4852208P 2008-04-28 2008-04-28
PCT/US2009/041981 WO2009134805A2 (en) 2008-04-28 2009-04-28 Antibodies to granulocyte-macrophage colony-stimulating factor

Publications (1)

Publication Number Publication Date
DK2280732T3 true DK2280732T3 (da) 2019-01-28

Family

ID=41255734

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09739607.1T DK2280732T3 (da) 2008-04-28 2009-04-28 Antistoffer mod granulocyt-makrofag-koloni-stimulerende faktor

Country Status (17)

Country Link
US (3) US8168183B2 (da)
EP (2) EP3449941A1 (da)
JP (1) JP5688363B2 (da)
KR (2) KR101824512B1 (da)
CN (1) CN102037016B (da)
AU (1) AU2009243184B2 (da)
BR (1) BRPI0911902A2 (da)
CA (1) CA2722137C (da)
CO (1) CO6311004A2 (da)
DK (1) DK2280732T3 (da)
EA (1) EA201001691A1 (da)
ES (1) ES2704835T3 (da)
IL (1) IL208980A (da)
MX (1) MX2010011761A (da)
NZ (1) NZ588850A (da)
WO (1) WO2009134805A2 (da)
ZA (1) ZA201008028B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2661848C (en) 2006-09-01 2015-02-03 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
JP5688363B2 (ja) 2008-04-28 2015-03-25 カロバイオス ファーマシューティカルズ インコーポレイティッド 顆粒球−マクロファージコロニー刺激因子に対する抗体
EP3381471B1 (en) 2008-12-22 2024-03-20 The University of Melbourne Pain treatment
CN106397591A (zh) * 2008-12-22 2017-02-15 墨尔本大学 骨关节炎治疗
WO2012012571A1 (en) 2010-07-21 2012-01-26 Hans Zassenhaus Biolayer interferometry measurement of biological targets
KR20140061379A (ko) 2011-07-06 2014-05-21 모르포시스 아게 항­ｃｄ20 및 항­ｇｍ­ｃｓｆ 항체의 치료 조합물 및 이의 용도
US9400600B2 (en) * 2011-12-16 2016-07-26 Samsung Electronics Co., Ltd. Method, apparatus, and graphical user interface for providing visual effects on a touchscreen display
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
US10745475B2 (en) * 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
BR112016025126B1 (pt) 2014-05-07 2024-02-15 Takeda Pharmaceutical Company Limited Composição aquosa compreendendo anticorpo neutralizante de gmcsf, e uso da mesma
CN113862300A (zh) * 2015-10-29 2021-12-31 豪夫迈·罗氏有限公司 具有共同轻链的转基因兔
SG11202003096UA (en) 2017-10-02 2020-05-28 Humanigen Inc Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
AU2019340662A1 (en) * 2018-09-10 2021-05-06 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
KR20210105344A (ko) 2018-10-31 2021-08-26 휴머니건, 아이엔씨. 암 치료용 물질 및 방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2003068920A2 (en) 2002-02-13 2003-08-21 Ludwig Institute For Cancer Research Humanized gm-csf antibodies
EP2135879A3 (en) * 2002-06-28 2010-06-23 Domantis Limited Ligand
US7575893B2 (en) * 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
WO2005069970A2 (en) * 2004-01-20 2005-08-04 Kalobios, Inc. Antibody specificity transfer using minimal essential binding determinants
EP2343380B1 (en) * 2004-11-16 2019-06-12 Humanigen, Inc. Immunoglobulin variable region cassette exchange
US7381802B2 (en) * 2005-04-15 2008-06-03 Universidad Nacional Autónoma De México (UNAM) Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom
ME02191B (me) * 2005-04-18 2016-02-20 Amgen Res Munich Gmbh Protutijela koja neutraliziraju ljudski čimbenik stimuliranja kolonija makrofaga
DK3620171T3 (da) * 2005-05-18 2022-06-07 Morphosys Ag Anti-GM-CSF-antistoffer og anvendelser af disse
US8211648B2 (en) 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
RU2008110060A (ru) * 2005-08-15 2009-09-27 Арана Терапьютикс Лимитед (Au) Сконструированные антитела с каркасными участками приматов нового света
PL1981909T3 (pl) * 2006-02-08 2017-08-31 Morphotek, Inc. Antygenowe peptydy GM-CSF oraz przeciwciała wobec GM-CSF
US8398972B2 (en) * 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
MX2009005398A (es) * 2006-11-21 2009-08-20 Kalobios Pharmaceuticals Inc Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
WO2009126659A1 (en) * 2008-04-07 2009-10-15 Kalobios Pharmaceuticals, Inc. Neutralization of gm-csf for the treatment of heart failure
JP5688363B2 (ja) 2008-04-28 2015-03-25 カロバイオス ファーマシューティカルズ インコーポレイティッド 顆粒球−マクロファージコロニー刺激因子に対する抗体

Also Published As

Publication number Publication date
MX2010011761A (es) 2010-11-30
US20120213776A1 (en) 2012-08-23
EA201001691A1 (ru) 2011-10-31
EP2280732A2 (en) 2011-02-09
IL208980A (en) 2015-06-30
US20090274706A1 (en) 2009-11-05
US8168183B2 (en) 2012-05-01
EP2280732B1 (en) 2018-10-17
CN102037016B (zh) 2015-06-03
KR20170126458A (ko) 2017-11-17
US20150344565A1 (en) 2015-12-03
JP5688363B2 (ja) 2015-03-25
JP2011518886A (ja) 2011-06-30
CA2722137A1 (en) 2009-11-05
US9017674B2 (en) 2015-04-28
KR20110011638A (ko) 2011-02-08
AU2009243184B2 (en) 2015-06-04
CO6311004A2 (es) 2011-08-22
CN102037016A (zh) 2011-04-27
NZ588850A (en) 2012-12-21
BRPI0911902A2 (pt) 2015-10-13
KR101824512B1 (ko) 2018-02-02
WO2009134805A3 (en) 2010-06-03
ES2704835T3 (es) 2019-03-20
IL208980A0 (en) 2011-01-31
ZA201008028B (en) 2012-04-25
EP3449941A1 (en) 2019-03-06
CA2722137C (en) 2019-03-19
KR101852915B1 (ko) 2018-04-27
WO2009134805A2 (en) 2009-11-05
AU2009243184A1 (en) 2009-11-05
EP2280732A4 (en) 2012-11-14

Similar Documents

Publication Publication Date Title
DK2280732T3 (da) Antistoffer mod granulocyt-makrofag-koloni-stimulerende faktor
US11673962B2 (en) Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab
AU2008333985B2 (en) Antibodies to the PcrV antigen of pseudomonas aeruginosa
WO1992019759A1 (en) Reconstituted human antibody against human interleukin 6 receptor
BRPI0713300A2 (pt) anticorpo de neutralização, epìtopo na il-17 humana, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção do anticorpo, composição farmacêutica, e, uso de um anticorpo
AU2016369307A1 (en) Multi-specific antibody molecules having specificity for TNF-alpha, IL-17A and IL-17F
KR20110043786A (ko) 조작된 항-ｉｌ-13 항체, 조성물, 방법 및 용도
CA2904527A1 (en) Anti-cd25 antibodies and their uses
WO2014028748A1 (en) Interleukin 2 antibodies and antibody complexes
KR20230144596A (ko) 항 cd112r 항체 및 그의 용도
US20240067758A1 (en) Multi-specific antibodies and antibody combinations
JP2024530467A (ja) ヒトインターロイキン－４受容体アルファ抗体
RU2825460C1 (ru) Антитела к TSLP человека и их применение
JP2024521967A (ja) 抗ｉｌ－３６ｒ抗体及びその使用
TW202136308A (zh) 抗ｃｓｆ１ｒ分子及其用途